期刊文献+

不同程度慢性阻塞性肺疾病患者血浆抗凝血酶-Ⅲ水平的变化

Change of Plasma Antithrombin Ⅲ Level in Patients with Chronic Obstructive Pulmonary Disease of Different Degree
下载PDF
导出
摘要 目的检测不同程度慢性阻塞性肺疾病(COPD)患者血浆抗凝血酶-Ⅲ(AT-Ⅲ)水平并探讨其临床意义。方法根据肺功能将COPD组患者分为轻(25例,FEV1%Pre〉/-80%)、中(32例,50%≤FEVl%Pre(80%)、重(28例,30%≤FEV1%Pre〈50%)、极重(25例,FEV1%Pre^30%)四级,分别测定各级COPD患者血浆AT_Ⅲ表达水平并与健康对照组比较,分析AT-Ⅲ与第一秒用力肺活量占预计值的百分比(FEVl%Pre)的相关性。结果COPD患者血浆AT-Ⅲ活性(74.98士14.75)明显低于对照组(89.52士】4.06),t=4.485,各级COPD组之间血浆AT-Ⅲ活性差异有统计学意义(P〈0.01)。血浆AT-Ⅲ活性与FEVl%Pre呈正相关(r==0.435,P〈O.01)。结论COPD患者存在血液高凝状态,血浆AT.Ⅲ活性随COPD疾病严重程度进展而下降。所以监测AT-Ⅲ活性对防治COPD高凝状态的发生、发展有重要意义. Objective To study significance of serum antithrombin Ⅲ (AT-Ⅲ) in patients with chronic obstructive pulmonary disease and detect the change of AT-Ⅲ level in COPD patients of different degree. Methods COPD patients were divided in- to four groups:slight (25,FEV1%Pre≥80%),moderate (32,50%FEVl%Pre〈80%),serious (28,30%FEVl%Pre〈50%) and much serious (25, FEV1% Pre〈30%) groups strictly according to diagnosis standard. COPD patients were measured plasma levels of AT- Ⅲ expression and comparative analysis with the healthy control group AT- Ⅲ correlation with FEVIPre. Results The AT-Ⅲ level in patients with COPD was decreased significantly than that health control group. A- mong the patients groups, there also had distinctive difference (P〈0. 01). Plasma AT-Ⅲ and FEV1% were positively corre- lated(r=0. 435, P〈C0. 01). Conclusion A hypercoaguiability state existed in COPD patients. Moreover, the serum AT-Ill level showed a decreasing trend with the development of COPD stage So dynamic observation of AT-Ⅲ levels may have im- portant significance in estimation of the cases,prognosis and treatment in COPD patients.
作者 彭德珍
出处 《现代检验医学杂志》 CAS 2012年第2期63-65,共3页 Journal of Modern Laboratory Medicine
基金 广西壮族自治区卫生厅计划课题(编号:Z2011179)
关键词 慢性阻塞性肺疾病 抗凝血酶-Ⅲ 第一秒用力肺活量占预计值的百分比 chronic obstructive pulmonary disease antithrombin- Ⅲ FEV1% Pre
  • 相关文献

参考文献9

二级参考文献39

共引文献8279

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部